Contents

WHO	Expe	rt Committee on Drug Dependence	V
Abbre	viati	ons	vii
Introd	lucti	on	1
	_	s from international organizations on their work on the Ith element of the world drug problem	3
Palane		Update from the International Narcotics Control Board	3
,	1.2	Update from the United Nations Office on Drugs and Crime Update from the WHO Department of Essential Medicines and	4
		Health Products	6
		Update from the WHO Department of Mental Health and Substance Abuse	7
	1.5	Update from the WHO Department of HIV/AIDS	8
2. Prin	ciple	es for prioritizing and assessing substances as part of	
ECDD	's wo	rk	10
3. Upo	late	from the first Informal Working Group of the ECDD	11
4. Foll	ow-u	up on recommendations made by the ECDD at its	
thirty		enth meeting	12
		Acetylfentanyl	12
		MT-45	12
		para-Methoxymethylamphetamine (PMMA)	12
		α-Pyrrolidinovalerophenone (α-PVP)	12
		para-Methyl-4-methylaminorex (4,4´-DMAR)	13
	4.6	Methoxetamine (MXE)	13
	4.7	Phenazepam	13
5. Crit	ical ı	review of psychoactive substances	14
		U-47700	14
	5.2	Butyrfentanyl (butyrylfentanyl)	16
		4-Methylethcathinone (4-MEC)	17
	5.4	3-Methylmethcathinone (3-methyl- <i>N</i> -methylcathinone; 3-MMC)	19
	5.5	Ethylone (3,4-methylenedioxy-N-ethylcathinone; bk-MDEA; MEDEC)	21
	5.6	Pentedrone (α-methylaminovalerophenone)	22
	5.7	Ethylphenidate (EPH)	24
	5.8	Methiopropamine (MPA)	26
	5.9	MDMB-CHMICA	27
	5.10	5F-APINACA (5F-AKB-48)	29
	5.11	JWH-073	31
	5.12	XLR-11	33

6. Update	s .	35
6.1	Cannabis and cannabis resin	35
7. Follow-	up on recommendations from international meetings and	
consultations		
7.1	Follow-up on implementation of recommendations of UNGASS and of the	
	UNODC-WHO Expert Consultation on NPS	37
7.2	WHO and other agencies' surveillance mechanisms and lists	39
8. Future agenda items		
Acknowledgements		
References		